



**CENTER FOR CLINICAL AND
TRANSLATIONAL SCIENCE**

June 2018 Volume 4, Issue 7

We hope you enjoy this newsletter which is full of helpful information and opportunities! Also, be sure to check out our website at:

<https://umassmed.edu/ccts>

Dissemination and Implementation Science
What is it and Why is it Critical to Translational Science?

TUESDAY, JUNE 19, 2018 | 12-1 PM EDT REGISTER NOW

LEARNING OBJECTIVES:

1. Know what dissemination, implementation, implementation science and dissemination science are
 2. Understand the features of dissemination and implementation (D&I) research studies and what makes D&I research studies different from usual clinical trials
 3. Be able to identify funding sources for D&I research
-



RNA
Therapeutics
Institute

RNA Therapeutics: FROM BASE PAIRS TO BEDSIDES

We live in an exciting time for the RNA research community. Throughout the latter half of the 20th century, we believed that RNA's primary role was to intermediate between DNA and protein. Over the last three decades, those long-held beliefs have been shattered. From ncRNAs to RNAi, from CRISPR to circular RNAs, we have witnessed astonishing discoveries and equally amazing translation of these breakthroughs to therapy. Come and join the discussion as we explore the era of RNA therapeutics!

JUNE 28-29, 2018
UMass Medical School, Worcester, MA



Joint Keynote Speakers:

Victor Ambros
UMass Medical School
and
Gary Ruvkun
Harvard Medical School

Confirmed Speakers & Panelists

Rodolphe Barrangou, North Carolina State University

Kevin Fitzgerald, Alnylam Pharmaceuticals

Rachel Haurwitz, Caribou Biosciences

Narry Kim, Seoul National University

Arthur Krieg, Checkmate Pharmaceuticals

Craig Mello, UMass Medical School

Harry Noller, UC Santa Cruz

Dmitry Samarsky, Silence Therapeutics

Joan Steitz, Yale University

Lingling Chen, Shanghai Institute of Biochemistry & Cell Biology

Aur lie Gogenvalle, Universit  de Versailles Saint Quentin en Yvelines

Anastasia Khvorova, UMass Medical School

Adrian Krainer, Cold Spring Harbor Labs

Arthur Levin, Avidity Biosciences

Melissa Moore, Moderna Therapeutics

Olivia Rissland, University of Colorado

Phillip Sharp, MIT

Walter Strapps, Intellia

Poster abstract deadline: April 27, 2018

Registration deadline: May 1, 2018

#RNATx2018  @UMassMedRTI
www.umassmed.edu/RNATx

FUNDING OPPORTUNITIES

CCTS SPARK Program

Application Deadline: Rolling Basis

THE UMCCTS SPARK (Small Pilot and Research Knowledge) Program's priorities are to support studies that impact clinical care and research methodologies, support students and trainees, and provide access to funds to generate pilot and preliminary data for external grant submissions.

For more information please see <https://umassmed.edu/ccts/funding/spark-program/>

CCTS Small Conference Grants

Application Deadline: Rolling Basis

THE UMCCTS is pleased to offer Small Conference Grants (SCG). This funding facilitates the development of faculty-to-faculty networks within the University system.

For more information please see <https://umassmed.edu/ccts/funding/small-conference-grants/>

Open to researchers in Massachusetts, Connecticut and Rhode Island. Both non-profit and small for-profit agencies are eligible.

Alzheimer's Innovation Award (AIA)

The prevention of Alzheimer's disease is a bold aspiration; the U.S. National Plan to Address Alzheimer's disease sets the goal to effectively treat and prevent Alzheimer's by 2025. The **Alzheimer's Association** and **Johnson & Johnson Innovation** share this vision and have joined together to offer a unique opportunity to advance projects that are directed at translating their findings towards the development of innovative new therapeutic agents and advancing efforts to address the global crisis of Alzheimer's Disease. Massachusetts, Connecticut and Rhode Island have a uniquely dynamic, entrepreneurial and creative science and technology heritage, with an emphasis on the creation, commercialization and sustainment of disruptive technologies and solutions from its medical science-based companies and leading research institutes and universities.

The **Alzheimer's Innovation Award (AIA)** will work with research teams in **Massachusetts, Connecticut and Rhode Island** to seek out cutting edge research directed towards the development of new therapeutic small molecules that can progress to the clinical treatment of Alzheimer's disease and related dementias.

Both non-profit and small for-profit agencies are eligible. Small for-profit organizations with <=\$2MM investments (i.e. exclusion of for-profit entities with a >\$2MM series A) and must provide documentation verifying status.

Letters of Intent (LOI) must be received by 5:00 PM EST, June 25, 2018. Letters of Intent will not be accepted after this date. No exceptions will be made. All LOIs must be submitted online at <https://proposalcentral.altum.com>. No hard copies or emails will be accepted.

For those invited to submit a full proposal, applications must be received by 5:00 PM EST, August 10, 2018.

For more information:

Email: grantsapp@alz.org

2018 Alzheimer's Innovation Award Key Dates:

LOI Now Open

LOI deadline - June 25, 2018, 5:00 PM Eastern

Application deadline - August 10, 2018, 5:00 PM Eastern

Award notification - October 11, 2018, location TBD. **Please note:** The winner of this competition will be selected during this event.

Learning Opportunities

K Club 2.0

The UCCTS Research Career & Writing Group (K-Club 2.0) was established in 2007. The group meets every first and third Wednesday to provide information and feedback on academic career development and on preparing a Research Career Award application (NIH K Awards, VA Research Career Awards, CTSA K12 grants, etc.). Faculty receive feedback on CV developments, help on preparing NIH biosketches as well as a wealth of other information.

Where: 1st and 3rd Wednesday of the month from 4:00pm - 5:00pm in AS6-2072

More information: www.umassmed.edu/ccts/education/k-club

I Corps Program

APPLY NOW!

Application Deadline September 17, 2018.

Does your latest discovery have commercial value? Would a potential "customer" of your research welcome your technology, protocol, or intervention?

The **I-Corps Program at the UMCCTS**, a joint MassTERi/UMass Center for Clinical and Translational Science (UMCCTS) initiative, is designed to support the translation of biomedical research by providing early-stage education and strategic guidance to faculty, staff and students during the ideation phase of technology development.

Course starts on October 23, 2018. Please go to:

<https://umassmed.edu/ccts/education/i-corps-program-at-the-umccts/>

Questions? Contact Nate Hafer at 508-856-2511

**University of Massachusetts Medical School
Transdisciplinary Training in Cardiovascular Research (T32)**

Request for Trainee Applications

UMass has a cardiovascular T32 training grant entitled "Transdisciplinary Training in Cardiovascular Research" under the direction and senior leadership of Drs. Catarina Kiefe and John Keane. The program represents a unique opportunity for the institution to promote the entire spectrum (T0 – T5) of cardiovascular research on our campus. We are writing to request applications from trainees who wish to become part of this exciting program at the postdoctoral level. New trainees will join 4 other current trainees in the program.

For more information, including how to apply, contact Rebecca Gigliello at Rebecca.Gigliello@umassmed.edu

*******DID YOU KNOW?*******

M2D2 Receives Grant to Accelerate Innovation for U.S. Health Security

The Massachusetts Medical Device Development Center (M2D2) recently received a grant to drive innovation in the health security space. M2D2 will be one of eight programs in the country scouting innovative technologies and products that can be developed to solve healthcare challenges that extend beyond traditional vaccine and drug development. This opportunity will allow us to help businesses that create these technologies by connecting them with our network of corporate sponsors, mentors, and vast set of university resources.

Click here to read the full article:

<http://blogs.uml.edu/m2d2/2018/06/06/m2d2-receives-grant-to-accelerate-innovation-for-u-s-health-security/>

CTSA Program hubs collaborate to help researchers navigate regulatory environment

Three North Carolina Clinical and Translational Science Awards (CTSA) Program hubs have collaborated to create a platform for sharing regulatory expertise and best practices. The Regulatory Guidance for Academic Research of Drugs and Devices (ReGARDD) Program provides researchers with regulatory guidance, education, and consultative support, to ultimately help them move promising products and novel discoveries to clinical trials.

ReGARDD, which is coordinated by the hubs at Duke University, the Wake Forest School of Medicine, and the University of North Carolina at Chapel Hill (UNC-Chapel Hill) with partner RTI International, officially launched in 2015 and has been developing since. The program builds upon the existing services and knowledge of the North Carolina CTSA Program Regulatory Groups and the Research Triangle Park (RTP).

>> **READ THE FULL STORY.**

Visit the ReGARDD Program website.

*****Share Your Success!*****

Have you had research published that cites the UMass Center for Clinical and Translational Science? Has a patent been filed on technology developed using Center funding or resources? Did your pilot project receive external grant funding? Share it with us at ccts@umassmed.edu. Sharing your successes helps show the importance and the effect of the Center for Clinical and Translational Science at UMass.

STAY CONNECTED



University of Massachusetts Center for Clinical and Translational Science | Ambulatory Care Center, 362
Plantation Street, Worcester, MA 01605

[Unsubscribe nathaniel.hafer@umassmed.edu](mailto:nathaniel.hafer@umassmed.edu)

[Update Profile](#) | [About our service provider](#)

Sent by annette.rogers@umassmed.edu in collaboration with

Constant Contact 
[Try it free today](#)